Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis
The Laryngoscope · 2024
DOI: 10.1002/lary.31438 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Laryngoscope, 2024. Verfasst von Daniel M Beswick und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles, California, U.S.A. Hauptthemen laut MEDLINE: Cystic Fibrosis, Sinusitis, Rhinitis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Marshall and Margherite McComb Foundation, Cystic Fibrosis Foundation, NIDCD NIH HHS.
Abstract (Originalsprache)
Objectives
The 22‐question SinoNasal Outcome Test (SNOT‐22) assesses chronic rhinosinusitis (CRS) severity. We aimed to identify predictors of SNOT‐22 score improvement following highly effective modulator therapy (HEMT) initiation and to corroborate the SNOT‐22 minimal clinically important difference (MCID) in adults with cystic fibrosis (CF).
Methods
Prospective observational data was pooled from four studies across 10 US centers investigating people with CF (PwCF) and CRS. Three studies evaluated HEMT's impact on CRS. For participants enrolled prior to HEMT initiation, SNOT‐22 scores were obtained at baseline and after 3–6 months of HEMT. Multivariate regression identified predictors of improvement. Cronbach's alpha and four distribution‐based methods were used to assess internal consistency and calculate the MCID of the SNOT‐22.
Results
A total of 184 PwCF participated with mean baseline SNOT‐22 scores ranging from 18.1 to 56.7. Cronbach's alpha was ≥0.90 across sites. Participants at sites with pre‐ and post‐HEMT data reported improvement in SNOT‐22 scores after initiating HEMT (all p < 0.05). Worse baseline SNOT‐22 score (odds ratio (OR): 1.05, p < 0.001, 95% CI: 1.02–1.08), F508del homozygosity (OR: 4.30, p = 0.040, 95% CI: 1.14–18.99), and absence of prior modulator therapy (OR: 4.99, p = 0.017, 95% CI: 1.39–20.11) were associated with greater SNOT‐22 improvement. The mean MCID calculated via distribution‐based methods was 8.5.
Conclusion
Worse baseline sinonasal symptoms, F508del homozygosity, and absence of prior modulator therapy predicted greater improvement after HEMT initiation. The mean MCID for SNOT‐22 in PwCF is 8.5 points, similar to non‐CF individuals with CRS, and provides a threshold specifically for PwCF. The SNOT‐22 has strong internal consistency in PwCF. Level of Evidence 3 Laryngoscope , 134:3965–3973, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, University of California, Los Angeles, California, U.S.A.
- Department of Otolaryngology-Head and Neck Surgery, Columbia University, New York, New York, U.S.A.
- Division of Pulmonary Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A.
- Department of Biostatistics, National Jewish Health, Denver, Colorado, U.S.A.
- Department of Otolaryngology-Head and Neck Surgery, University of North Carolina, Chapel Hill, North Carolina, U.S.A.
- Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University, New York, New York, U.S.A.
ORCID-Profile: Daniel M Beswick, Christine M Liu, Jonathan B Overdevest, David A Gudis, Jessa E Miller, Jeremiah A Alt, Jivianne T Lee, Jayakar V Nayak, Zara M Patel, Timothy L Smith, Zachary M Soler
Förderung
- Marshall and Margherite McComb Foundation
- Cystic Fibrosis Foundation
- NIDCD NIH HHS
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Beswick, D. M., Liu, C. M., Overdevest, J. B., Zemke, A., Khatiwada, A., Gudis, D. A., Miller, J. E., Kimple, A., Tervo, J. P., DiMango, E., Goralski, J. L., Keating, C., Senior, B., Stapleton, A. L., Eshaghian, P. H., Mace, J. C., Markarian, K., Alt, J. A., Bodner, T. E., …, & Taylor Cousar, J. L. (2024). Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis. The Laryngoscope. https://doi.org/10.1002/lary.31438
Vancouver
Beswick DM, Liu CM, Overdevest JB, Zemke A, Khatiwada A, Gudis DA, et al. Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis. The Laryngoscope. 2024. doi:10.1002/lary.31438
BibTeX
@article{Beswick2024,
author = {Beswick, Daniel M and Liu, Christine M and Overdevest, Jonathan B and Zemke, Anna and Khatiwada, Aastha and Gudis, David A and Miller, Jessa E and Kimple, Adam and Tervo, Jeremy P and DiMango, Emily and Goralski, Jennifer L and Keating, Claire and Senior, Brent and Stapleton, Amanda L and Eshaghian, Patricia H and Mace, Jess C and Markarian, Karolin and Alt, Jeremiah A and Bodner, Todd E and Chowdhury, Naweed I and Getz, Anne E and Hwang, Peter H and Khanwalker, Ashoke and Lee, Jivianne T and Li, Douglas A and Norris, Meghan and Nayak, Jayakar V and Owens, Cameran and Patel, Zara M and Poch, Katie and Schlosser, Rodney J and Smith, Kristine A and Smith, Timothy L and Soler, Zachary M and Suh, Jeffrey D and Turner, Grant A and Wang, Marilene B and Saavedra, Milene T and Taylor Cousar, Jennifer L},
title = {Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31438}
}
EUVIMED